A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta’s
annual sales.
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention
deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
Indianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of
loss of revenue that it’s hard to picture what the company will look like in five years.
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said.
Ascendis may choose a final bidder by early September.
A U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013.
Gemzar generated $1.36 billion in global sales in 2009.
Investors are focused on whether Eli Lilly and Co. can continue dividend payments when patent expirations hit in the new few
years and whether the company's drug development pipeline can replace lost revenue.
Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week
when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses
of the disease.
The Indianapolis-based drugmaker eliminated 140 information technology jobs in June through retirements, resignations and some cuts. Another 115
cuts will be made this month, and the remainder by the end of the year.
Both of Lilly’s late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer’s. A drug that stops or reduces memory loss caused by Alzheimer’s may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the
end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling
drugs.
Concentrics grows in spite of recession as drug companies look for help to handle patent expirations
The global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish
patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no
mega-merger.
The findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly’s Cialis, may be more likely to
engage in unsafe sex than nonusers.
Massachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years,
recently submitted its drug to the FDA for market approval.
U.S. Senator Charles Grassley asked 16 drugmakers, including Eli Lilly & Co., Pfizer Inc. and AstraZeneca Plc, to reveal
how they treat whistleblowers who file complaints under the False Claims Act.
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.
Roche Holding AG’s decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals
Inc. and drug partner Eli Lilly and Co.
Despite losses, company sees growth in its DailyMed pharmacy services, which packages the right dosages of prescriptions to
make it easier for patients to follow their regimens.
